Genetic characterization of N-acetyltransferase 2 variants in acquired multidrug-resistant tuberculosis in Indonesia

Author:

Yuliwulandari Rika12ORCID,Prayuni Kinasih2,Razari Intan3,Susilowati Retno W24,Zulhamidah Yenni5,Soedarsono Soedarsono67,Sofro Abdul Salam M89,Tokunaga Katsushi10

Affiliation:

1. Department of Pharmacology, Faculty of Medicine, YARSI University, Jakarta, Indonesia

2. Genetic Research Center, YARSI Research Institute, YARSI University, Jakarta, Indonesia

3. YARSI Research Institute, YARSI University, Jakarta, Indonesia

4. Department of Histology, Faculty of Medicine, YARSI University, Jakarta, Indonesia

5. Department of Anatomy, Faculty of Medicine, YARSI University, Jakarta, Indonesia

6. Department of Pulmonology & Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

7. Dr. Soetomo General Hospital, Surabaya, Indonesia

8. Graduate School, YARSI University, Jakarta, Indonesia

9. Department of Biochemistry, Faculty of Medicine, YARSI University, Jakarta, Indonesia

10. Genome Medical Science Project (Toyama), National Center for Global Health & Medicine, Tokyo, Japan

Abstract

Background: Owing to the high resistance rate of tuberculosis (TB) to isoniazid, which is metabolized by N-acetyltransferase 2 (NAT2), we investigated the associations between NAT2 variants and multidrug-resistant (MDR)-TB. Materials & methods: The acetylator status based on NAT2 haplotypes of 128 patients with MDR-TB in Indonesia were compared with our published data from patients with anti-TB drug-induced liver injury (AT-DILI), TB and the general population. Results: NAT2*4 was more frequent in the MDR-TB group than in the AT-DILI group, TB controls and general controls. NAT2*4/*4 was significantly more frequent in patients with MDR-TB than in those with AT-DILI. NAT2*5B/7B, *6A/6A and *7B/*7B were detected at lower frequencies in patients with AT-DILI. Rapid acetylators were significantly more frequent in patients with MDR-TB than in those with AT-DILI. Conclusion: These results provide an initial data for optimizing TB treatment in the Indonesian population, and suggest that NAT2 genotyping may help to select appropriate treatment by predicting TB-treatment effect.

Funder

Kementerian Riset Teknologi Dan Pendidikan Tinggi Republik Indonesia

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Reference23 articles.

1. WHO. Global Tuberculosis Report 2019 (2019). https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf

2. What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?

3. Molecular mechanisms of isoniazid: a drug at the front line of tuberculosis control

4. World Health Organization. WHO Treatment Guidelines for Isoniazid-Resistant Tuberculosis: Supplement to the WHO Treatment Guidelines for Drug-Resistant Tuberculosis (2018). https://www.who.int/tb/publications/2018/WHO_guidelines_isoniazid_resistant_TB/en/

5. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3